(IMAGE: PHOTOS.COM/MELISSA MCEVOY)

Regulatory sands are shifting in uncertain ways both here and abroad. FDA is changing both philosophically and operationally, with initiatives such as Quality by Design, Process Analytical Technology, and the Critical Path. Of course, as the industry abroad matures, so do overseas regulations. And that necessitates efforts to standardize regulations so firms can operate smoothly and efficiently, and so drugs are of uniform quality, in multiple markets. Taken together, the current picture is one of an industry in flux. So, we couldn't resist asking industry experts how they think it will all shake out. What, we asked, will the pharmaceutical industry look like in 2037 when Pharmaceutical Technology celebrates its 60th anniversary? The following is an edited version of their replies. Jim Miller, Pharmaceutical Technology's columnist on outsourcing and president of PharmSource Information Services, may have summed it all up best when he said, "New players, new technologies, new geographies—in 30 years, it won't be your parents'... industry."

Michelle Hoffman, editor-in-chief,
Pharmaceutical Technology

Strategy and Regulation
Outsourcing
Solid-Dosage Formulation
Ingredients
Drug Delivery
Packaging
Analytical Testing
Information Technology